BeyondSpring Inc. Ordinary Shares
$0.71
$0.00 (+0.00%)
$0.70Day Range$0.73
Key Statistics
Market Cap
$29.15M
Shares Outstanding
41.1M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Mar 9, 2017
Round Lot
100
Locale
US
Trading Data
Day Open
$0.71
Day High
$0.73
Day Low
$0.70
Volume
37.2K
VWAP
$0.72
Prev Close
$0.71
Transactions
--
Acc. Volume
--
About BeyondSpring Inc. Ordinary Shares
BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It operates in Plinabulin pipeline segment. Its first asset, Plinabulin is a novel brain-penetrant microtubule modulator with dendritic cell maturation and vasculature modulation mechanism, which has the potential to help mitigate acquired resistance from prior immune checkpoint inhibitors (ICI) treatment in cancer patients. It is a Selective Immunomodulating Microtubule-Binding Agent (SIMBA), which may provide multiple therapeutic opportunities.
PHARMACEUTICAL PREPARATIONSSIC 283444 employees100 CAMPUS DRIVE, WEST SIDE, 4TH FLOOR, FLORHAM PARK, NJ, 07932646-528-4184IPO Mar 9, 2017US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001677940
- Ticker Root
- BYSI
- SIC Code
- 2834
About BeyondSpring Inc. Ordinary Shares (BYSI) Stock
BeyondSpring Inc. Ordinary Shares (BYSI) closed the 2026-09-17 session at $0.71, up 0.00% versus the previous close (+0.00). The stock opened at $0.71 and traded between $0.70 and $0.73 during that session. Session trading volume was 37K shares. The volume-weighted average price (VWAP) is $0.72.
BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It operates in Plinabulin pipeline segment. Its first asset, Plinabulin is a novel brain-penetrant microtubule modulator with dendritic cell maturation and vasculature modulation mechanism, which has the potential to help mitigate acquired resistance from prior immune checkpoint inhibitors (ICI) treatment in cancer patients. It is a Selective Immunomodulating Microtubule-Binding Agent (SIMBA), which may provide multiple therapeutic opportunities.
BeyondSpring Inc. Ordinary Shares has a market capitalization of $29.1 million. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. BYSI is listed on the XNAS exchange. The company employs approximately 44 people. BeyondSpring Inc. Ordinary Shares is headquartered in FLORHAM PARK, NJ. The recorded listing date is 2017-03-09.
On this page you can find market BYSI stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.